Clinical trial
Ceftobiprole in the Treatment of Resistant Staphylococcus Aureus Skin and Skin…
NCT00210899 · Basilea Pharmaceutica, Industry · Completed
Key facts
| NCT number | NCT00210899 |
|---|---|
| Title | Ceftobiprole in the Treatment of Resistant Staphylococcus Aureus Skin and Skin Structure Infections |
| Official title | A Phase III, Randomized, Double-Blind Study of Ceftobiprole Versus Comparator in the Treatment of Complicated Skin and Skin Structure Infections |
| Lead sponsor | Basilea Pharmaceutica, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Skin Diseases, Infectious, Bacterial, Staphylococcal Skin Infections |
| Intervention type | Drug |
| Interventions | ceftobiprole medocaril, Vancomycin plus Ceftazidime |
| Enrollment | 828 |
| Start date | Sep 1, 2005 |
| Primary completion | Oct 1, 2006 |
| Completion | Oct 1, 2006 |
| First posted | Sep 21, 2005 |
| Last update posted | Jul 26, 2012 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: